Lexeo’s Approach To Gene Therapy For Common Conditions
CEO Expects First Commercial Launch As Early As 2026
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
